[go: up one dir, main page]

WO2008064031A3 - Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses - Google Patents

Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses Download PDF

Info

Publication number
WO2008064031A3
WO2008064031A3 PCT/US2007/084600 US2007084600W WO2008064031A3 WO 2008064031 A3 WO2008064031 A3 WO 2008064031A3 US 2007084600 W US2007084600 W US 2007084600W WO 2008064031 A3 WO2008064031 A3 WO 2008064031A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
regulation
role
immune responses
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/084600
Other languages
French (fr)
Other versions
WO2008064031A9 (en
WO2008064031A2 (en
Inventor
Gerardo Kaplan
Maria Cecilia Tami
Mohanraj Manangeeswaran
Rosemarie Dekruyff
Dale Umetsu
Gordon Freeman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of WO2008064031A2 publication Critical patent/WO2008064031A2/en
Publication of WO2008064031A3 publication Critical patent/WO2008064031A3/en
Anticipated expiration legal-status Critical
Publication of WO2008064031A9 publication Critical patent/WO2008064031A9/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention relates to the identification of IgAλ as a ligand for HAVCR1/TIM1, the receptor for Hepatitis A Virus. The invention provides compositions for inhibiting or promoting this interaction, and methods for influencing immunologic responses to antigens by administration of compounds that affect binding of IgAλ to HAVCR1/TIM1.
PCT/US2007/084600 2006-11-13 2007-11-13 Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses Ceased WO2008064031A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86563106P 2006-11-13 2006-11-13
US60/865,631 2006-11-13

Publications (3)

Publication Number Publication Date
WO2008064031A2 WO2008064031A2 (en) 2008-05-29
WO2008064031A3 true WO2008064031A3 (en) 2009-03-12
WO2008064031A9 WO2008064031A9 (en) 2009-08-06

Family

ID=39430491

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/084600 Ceased WO2008064031A2 (en) 2006-11-13 2007-11-13 Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses

Country Status (1)

Country Link
WO (1) WO2008064031A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088219A2 (en) * 2010-01-13 2011-07-21 The Uab Research Foundation Therapeutics and processes for treatment of immune disorders
DK2808028T3 (en) 2011-11-21 2019-10-07 Univ Tsukuba ACTIVITY MODULATOR, MEDICAL AGENT COMPREHENSIVE SAME, USE OF MICE WITH CD300A GEN deficiency and ANTI-CD300A ANTIBODY
JP6226333B2 (en) 2012-11-07 2017-11-08 国立大学法人 筑波大学 Drugs containing an activity regulator of CD300a expressing cells related to allergic diseases, and use of CD300a gene-deficient mice and CD300a expressing cells
US10794899B2 (en) 2014-12-05 2020-10-06 Fujifilm Wako Pure Chemical Corporation Tim protein-bound carrier, methods for obtaining, removing and detecting extracellular membrane vesicles and viruses using said carrier, and kit including said carrier
WO2018049130A1 (en) * 2016-09-09 2018-03-15 The General Hospital Corporation Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of infectious diseases
US11197910B1 (en) * 2020-08-19 2021-12-14 Vitruviae LLC Fusion proteins for the diagnosis, prophylaxis and treatment of infectious diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014475A1 (en) * 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
WO2005027854A2 (en) * 2003-09-15 2005-03-31 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
WO2006094134A2 (en) * 2005-03-02 2006-09-08 Biogen Idec Ma Inc. Kim-1 antibodies for treatment of th2-mediated conditions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014475A1 (en) * 1992-12-21 1994-07-07 Tanox Biosystems, Inc. ALLERGEN-SPECIFIC IgA MONOCLONAL ANTIBODIES AND RELATED PRODUCTS FOR ALLERGY TREATMENT
WO2005027854A2 (en) * 2003-09-15 2005-03-31 The Board Of Trustees Of The Leland Stanford Junior University T cell regulatory genes associated with immune disease
WO2006094134A2 (en) * 2005-03-02 2006-09-08 Biogen Idec Ma Inc. Kim-1 antibodies for treatment of th2-mediated conditions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KUCHROO V K ET AL: "THE TIM GENE FAMILY: EMERGING ROLES IN IMMUNITY AND DISEASE", NATURE REVIEWS. IMMUNOLOGY, XX, XX, vol. 3, 1 June 2003 (2003-06-01), pages 454 - 462, XP008039531, ISSN: 1474-1733 *
MCINTIRE J J ET AL: "TIM-1, a novel allergy and asthma susceptibility gene", SPRINGER SEMINAR IN IMMUNOPATHOLOGY, SPRINGER VERLAG, DE, vol. 25, 1 February 2004 (2004-02-01), pages 335 - 348, XP002353109, ISSN: 0344-4325 *

Also Published As

Publication number Publication date
WO2008064031A9 (en) 2009-08-06
WO2008064031A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
WO2008064031A3 (en) Potent activation of antigen presenting cells by the hepatitis a virus cellular receptor 1 and its role in the regulation of immune responses
MY171841A (en) Antibody formulation
WO2006119107A3 (en) Sclerostin binding agents
WO2006119062A3 (en) Sclerostin epitopes
WO2009070243A3 (en) Wise binding antibodies and epitopes
WO2007106744A8 (en) Anti-5t4 antibodies and uses thereof
WO2008013454A3 (en) Immunogenic compounds and protein mimics
ZA200907385B (en) Binding proteins, including antibodies, antibody derivative and antibody fragments, that specifically bind cd154 and uses thereof
WO2006116423A3 (en) Compositions and methods for cancer immunotherapy
IL229778A0 (en) Novel anti-igf-ir antibodies, uses thereof and compositions comprising same
WO2013043933A3 (en) Cd27l antigen binding proteins
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
WO2011008974A3 (en) Rsv f protein compositions and methods for making same
IL204607A0 (en) Antibodies against osteoclast - related protein siglec - 15, compositions comprising the same and uses thereof
SG196835A1 (en) Human anti-b7rp1 neutralizing antibodies
WO2006121422A8 (en) Antibodies against clostridium difficile toxins and uses thereof
WO2008123999A3 (en) Anti-ige antibodies
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
WO2007105115A3 (en) Compositions and methods for immunisation using cd1d ligands
WO2007102736A3 (en) Interfering in activation of an immune cell by influencing interaction of lair and collagen.
FR2922767B1 (en) PROCESS FOR PREPARING A VACCINE COMPOSITION COMPRISING AT LEAST ONE ANTIGEN AND AT LEAST ONE ADJUVANT
WO2006012621A3 (en) Compositions and methods for regulating the alternative pathway of complement
WO2009034473A3 (en) Gas57 mutant antigens and gas57 antibodies
WO2012144726A3 (en) Tumor antigen proteins or genes of polo-like kinase 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07868749

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07868749

Country of ref document: EP

Kind code of ref document: A2